RNAZ on XNAS, Health Care, TransCode Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 86% in 12 months to $1.16 as a $145.4M net loss dwarfs $4.6M of cash.
BadNet cash just $1.5M after $3.1M of debt
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $107.4M.
31 Dec 2021RevenueNet incomeNet losstallest bar $107.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$107.4M
30 Jun 2026
–
-$6.8M
31 Mar 2026
–
-$17.8M
31 Dec 2025
–
-$13.4M
30 Sep 2025
–
-$4.9M
30 Jun 2025
–
-$4.3M
31 Mar 2025
–
-$12.1M
31 Dec 2024
–
-$5.9M
30 Sep 2024
–
-$2.3M
30 Jun 2024
–
-$5.2M
31 Mar 2024
–
-$3.3M
31 Dec 2023
–
-$4.1M
30 Sep 2023
–
-$5.3M
30 Jun 2023
–
-$4.3M
31 Mar 2023
–
-$4.8M
31 Dec 2022
–
-$5.1M
30 Sep 2022
–
-$4.3M
30 Jun 2022
–
-$4.7M
31 Mar 2022
–
-$3.5M
31 Dec 2021
–
-$2.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$145.4M
-$27.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$9.29
-$570.10
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-866%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$4.6M
$2.8M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$3.1M
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.5M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.10
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.86
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.62
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
–
No data for this company
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
0.6%
100K shares held by 13F filers (30 Sep 2026) of 17.3M outstanding (12 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.3%
52K shares sold short (30 Oct 2026) of 17.3M outstanding (12 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.0
52K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.4%
55K shares sold short in the report before, 52K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
30%
30% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
8
8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $1.16 on 20 Nov 2026, -86% over 12 months (12-month range $1.16 to $12.34)
Sharp change
8-K and other filings
Federal award
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).Capital spending per quarter. Capital spending $500 in the latest quarter.Institutional holders (13F filers). 12 13F filers reported holding it in the latest 13F quarter, +50% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2021: $75K; public on 17 May 2022
Quarter ended 31 Dec 2021: $86K; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $31K, -59% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $42K, +89% on a year earlier; public on 16 Aug 2022
Quarter ended 31 Dec 2022: $28K, -67% on a year earlier; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $13K, -58% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $18K, -57% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $5K; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $4K, -70% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $5K, -75% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $13K, +179% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $500; public on 16 Apr 2025
Institutional holders (13F filers)
31 Dec 2021 report: 15; public on 14 Feb 2022
31 Mar 2022 report: 13; public on 16 May 2022
30 Jun 2022 report: 13; public on 15 Aug 2022
30 Sep 2022 report: 12; public on 14 Nov 2022
31 Dec 2022 report: 16; public on 14 Feb 2023
31 Mar 2023 report: 10; public on 15 May 2023
30 Jun 2023 report: 4; public on 14 Aug 2023
30 Sep 2023 report: 10; public on 14 Nov 2023
31 Dec 2023 report: 14; public on 14 Feb 2024
31 Mar 2024 report: 6; public on 15 May 2024
30 Jun 2024 report: 14; public on 14 Aug 2024
30 Sep 2024 report: 8; public on 14 Nov 2024
31 Dec 2024 report: 4; public on 14 Feb 2025
31 Mar 2025 report: 16; public on 15 May 2025
30 Jun 2025 report: 7; public on 14 Aug 2025
30 Sep 2025 report: 8; public on 14 Nov 2025
31 Dec 2025 report: 6; public on 17 Feb 2026
31 Mar 2026 report: 8; public on 15 May 2026
30 Jun 2026 report: 9; public on 14 Aug 2026
30 Sep 2026 report: 12; public on 16 Nov 2026
Federal obligations
Month from 1 Jul 2022: $1.1M published
Month from 1 Nov 2022: $0 published
Month from 1 May 2023: $871K published
Month from 1 Oct 2024: $1.0M published
Month from 1 Jul 2025: $989K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is operating income, quarter at -$109.7M (30 Sep 2026), 2172% below its normal quarter of -$4.8M; higher than 4% of its own history.
No new award in 12 months; the latest was signed 4 Sep 2024. New awards only; later changes to an award are not listed.
Signed
Agency
Amount
What for
Source
4 Sep 2024
Department of Health and Human ServicesNational Institutes of Health
$2.0M
PHASE I CLINICAL TESTING OF A FIRST-IN-CLASS THERAPY AGAINST METASTATIC CANCER - SUMMARY METASTATIC DISEASE IS RESPONSIBLE FOR ~90% OF CANCER DEATHS AND IS THE PRIMARY DETERMINANT IN THE LIFE-LIMITING ASPECT OF CANCER. ONE VALIDATED DRIVER OF METASTASIS IS MIRNA-10B, A NON-CODING RNA ASSOCIATED WITH METASTATIC PROGRESSION IN NUMEROUS PRECLINICAL AND > 100 CLINICAL STUDIES. TRANSCODE HAS DEVELOPED A NOVEL THERAPEUTIC AGENT (TERMED MN-ANTI-MIR10B AND COMMERCIALLY DEVELOPED AS TTX-MC138) THAT RELIEGrant
In 12 months: 2 director or officer changes, 2 major agreements, 1 late report, 1 share registration. Results releases and routine reports are left out.
Filed
What happened
Source
1 Oct 2026
Signed a major agreementSame filing: a debt came due early
Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: sold shares privately, changed shareholder rights, changed its bylaws or fiscal year
Two or more unrelated kinds of records unusual within 30 days
15 Oct 2024confirmed
Confirmed across sources Government contracts and Short interest and volume
TransCode Therapeutics(RNAZ): won its first federal award in our data, a $1.0M Department of Health and Human Services grant, while it had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year. Two unrelated kinds of activity within 10 days.
Government contracts: First federal award, became public on 5 Oct 2024
Short interest and volume: Short interest spike, became public on 10 Oct 2024
The 30 Sep 2024 report against the 24 reports before it.
this reportearliernormal: 250KSee the evidence (2 changes)
Government contracts: First federal award became public on 5 Oct 2024
TransCode Therapeutics won its first federal award in our data, a $1.0M Department of Health and Human Services grant.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 10 Oct 2024
TransCode Therapeutics had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.
This period
1.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
250K
Typical spread (median absolute deviation)
182K
How far from its usual level
+4.2
Same report last year
73K
History used
1,173 days
the 30 Sep 2024 report24 earlier reportsnormal: 250K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
11 Sep 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 2.6M shares sold short in the 31 Mar 2025 report, 64× the same report last year.
Same report last year: 40K; its normal report is 247K.
See the evidence
This period
2.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
247K
Typical spread (median absolute deviation)
198K
How far from its usual level
+7.9
Same report last year
40K
History used
1,355 days
the 31 Mar 2025 report24 earlier reportsnormal: 247K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
won its first federal award in our data, a $1.0M Department of Health and Human Services grant, while it had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year. Two unrelated kinds of activity within 10 days.
See the evidence (2 changes)
Government contracts: First federal award became public on 5 Oct 2024
TransCode Therapeutics won its first federal award in our data, a $1.0M Department of Health and Human Services grant.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 10 Oct 2024
TransCode Therapeutics had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.
This period
1.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
250K
Typical spread (median absolute deviation)
182K
How far from its usual level
+4.2
Same report last year
73K
History used
1,173 days
the 30 Sep 2024 report24 earlier reportsnormal: 250K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Oct 2024Short interest and volume change
had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.
Same report last year: 73K; its normal report is 250K.
See the evidence
This period
1.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
250K
Typical spread (median absolute deviation)
182K
How far from its usual level
+4.2
Same report last year
73K
History used
1,173 days
the 30 Sep 2024 report24 earlier reportsnormal: 250K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.6M shares sold short in the 31 Jul 2024 report, 111× the same report last year.
Same report last year: 15K; its normal report is 174K.
See the evidence
This period
1.6M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
174K
Typical spread (median absolute deviation)
153K
How far from its usual level
+6.4
Same report last year
15K
History used
1,112 days
the 31 Jul 2024 report24 earlier reportsnormal: 174K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 31 May 2024 report, 37× the same report last year.
Same report last year: 27K; its normal report is 138K.
See the evidence
This period
1.0M (the 31 May 2024 report)
Normal report (median of 24 earlier)
138K
Typical spread (median absolute deviation)
104K
How far from its usual level
+5.7
Same report last year
27K
History used
1,051 days
the 31 May 2024 report24 earlier reportsnormal: 138K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 31 Oct 2023 report, 6.0× the same report last year.
Same report last year: 219K; its normal report is 209K.
See the evidence
This period
1.3M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
209K
Typical spread (median absolute deviation)
190K
How far from its usual level
+4.0
Same report last year
219K
History used
838 days
the 31 Oct 2023 report24 earlier reportsnormal: 209K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 68 entries; narrow the window or the kind of data to see older ones.
Not listed: 75 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001829635
Ticker
RNAZ
Domain
transcodetherapeutics.com
Hq location
MA|BOSTON|02109 (1 unverified)
Name
TransCode Therapeutics, Inc.
Uei
M4SWK8BE2J85
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)117 records26 Feb 2021 to 16 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)321 data points31 Dec 2019 to 12 Nov 2026
SEC Form 4 insider transactions8 records, 24 data points1 Jun 2022 to 2 Oct 2023
FINRA short interest (twice monthly)380 data points15 Jul 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2698 data points9 Jul 2021 to 20 Nov 2026
USASpending.gov federal awards1 record, 21 data points16 Apr 2021 to 19 Jun 2025